ethocyn reviews
According to dermatologists, loss of elastin fibers is the single most common reason behind age-related skin changes like wrinkles and sagging skin.
We, Health Web Magazine, the owner of this e-commerce website, fully intends to comply with the rules of the Federal Trade Commission (FTC) regarding the use of endorsements, testimonials, and general advertising and marketing content. As a visitor to Health Web Magazine you should be aware that we may receive a fee for any products or services sold through this site.
Content
This content may contain all or some of the following – product information, overviews, product specifications, and buying guides. All content is presented as a nominative product overview and registered trademarks, trademarks, and service-marks that appear on Health Web Magazine belong solely to their respective owners. If you see any content that you deem to be factually inaccurate, we ask that you contact us so we can remedy the situation. By doing so, we can continue to provide information that our readers can rely on for truth and accuracy.
Our Top Selections Box – Promotional Sales
Products shown in the section titled ‘Our Top Products’ are those that we promote as the owner and/ or reseller and does not represent all products currently on the market or companies manufacturing such products. In order to comply fully with FTC guidelines, we would like to make it clear that any and all links featured in this section are sales links; whenever a purchase is made via one of these links we will receive compensation. Health Web Magazine is an independently owned website and all opinions expressed on the site are our own or those of our contributors. Regardless of product sponsor relations, all editorial content found on our site is written and presented without bias or prejudice.
Something we believe is that every page on the website should be created for a purpose. Our Quality Page Score is therefore a measurement of how well a page achieves that purpose. A page’s quality score is not an absolute score however, but rather a score relative to other pages on the website that have a similar purpose. It has nothing to do with any product ratings or rankings. It’s our internal auditing tool to measure the quality of the on the page content. There are a number of factors that determine the Page Score of a given page. Landing page quality is a factor in determining Page Score. Landing page quality generally refers to whether or not the overall page contains relevant and original content to the web page visitor. The content quality value of a web page is determined by comparing a page to known quality patterns and each pattern carries a different weighting in how it affects the overall content quality value of a page. We also factor in user generated feedback on this form plus a page quality algorithm. Since web pages content can change, the content quality value of a web page is updated periodically.
Ethocyn was developed by Chantal Burnison, chief executive officer and chairman of the company, with a team of research scientists. A chemist, biologist, businesswoman and attorney, Burnison has developed the only antiaging solution on the market that actually helps increase elastin tissue to improve the skin’s natural tone and texture, according to the spokesman.
Support for Ethocyn increased by Chantal.
EL SEGUNDO, Calif. – In a category in which many products have been long on promises and short on results, Chantal Pharmaceutical Corp. has formulated the Ethocyn line for what executives say is truly effective skin care.
And with an expanded management team along with new sales and marketing initiatives, the supplier is poised to build Ethocyn into the No. 1 skin care product sold in drug stores, according to a company spokesman.
Ethocyn products reached second place in the trade class last year with only 5% distribution compared with 86% distribution for the top-selling brand, he says. Ethocyn is now seeking the No. 1 ranking among skin care lines with just 45% distribution.
Ethocyn, which the spokesman notes was the first product in the category to break price barriers, continues to sell with its two main SKUs at a suggested price of $120 and $75. But new programs and products, including an introductory trial kit, will allow first-time users to purchase Ethocyn for $39.
Ethocyn was developed by Chantal Burnison, chief executive officer and chairman of the company, with a team of research scientists. A chemist, biologist, businesswoman and attorney, Burnison has developed the only antiaging solution on the market that actually helps increase elastin tissue to improve the skin’s natural tone and texture, according to the spokesman.
Marketing and distribution of Ethocyn were recently integrated into Chantal’s operations. Essential to the change in direction was the appointment of Joe DeKama as executive vice president of Chantal and president of its Chantal Skin Care Corp. subsidiary.
DeKama brings the marketing and distribution experience of more than 35 years in the cosmetics and fragrance industry. He was executive vice president of sales and marketing at Faberge from 1972 to 1979, building the brand’s volume to $250 million. Prior to that he was senior vice president at Winarick for more than five years.
Since 1979 DeKama has successfully marketed and distributed nationally recognized cosmetics and fragrance brands in the United States and Canada, including Nature’s Organics Plus and LaSalle 10. Most recently, he developed the DCA fragrances and lipsticks for Tristar Corp.
“I’ve had my eye on Ethocyn since it was first introduced and look forward to working with Chantal and the new management, delivering the product to its rightful leadership position in the industry,” says DeKama.
He plans to introduce Ethocyn to retail powers, including Rite Aid Corp., CVS Corp. and Cosmetics Plus. Chantal is also in the process of developing an Ethocyn product configuration exclusively for department stores nationwide.
Since joining the company in June, DeKama has attracted a seasoned sales force that includes Michael Cavalaris of CDZ Sales Inc., Chuck Mitchell of L’Amorueaux Sales & Marketing, Joe Millin of Valor Marketing, Coleman Jackson of Hynes Dowell, Fred O’Kasick of Fred O’Kasick Sales Inc., Mary Cardell of KKM Inc., Dennis Casle and Carol Crafton of MGR & Associates, and Rich and Mary Landers of Landers & Associates Inc.
Prior to making the decision to launch its own skin care line Chantal was approached by numerous cosmetics industry leaders who sought to license the Ethocyn ingredient for use in their own brands, according to the spokesman.
To support the line Chantal has unveiled an aggressive multimillion-dollar ad campaign. The initiative will break in September and includes national network and cable television commercials, radio spots, and ads in such consumer magazines as Vogue, Town & Country and W.
The supplier will also continue its Ethocyn product promotions, including the endorsement by the cast of Baywatch, the No. 1 TV program in the world with over 1 billion viewers per week.
Chantal is researching, developing and marketing other proprietary and science-based skin care products. A new sun care line called Ethocyn Safe Sun will be introduced, with distribution beginning in late fall for sale in spring/summer 1998. An Ethocyn-based men’s product line is scheduled for test launch in Europe by the end of 1997.
“Ethocyn’s efficacy stands alone and without competition in the cosmetic treatment products industry,” says Burnison. “It is not a moisturizer or another alpha-hydroxy product.”
Because when the skin ages, the enzymes which keep the skin hydrated begin to slow in their production, the Chantal manufacturers spent years of time and millions of dollars to come up with an active ingredient called Ethocyn that can help the skin in producing more elastin fibres, therefore, help it repossess its firmness, only after using the product a few times. Some of the other ingredients found in Chantal Ethocyn skin care line are the following: Cyclomethicone, Squalance, Demithicone, Green Tee Leaf Extract, Tocopheryl Linoleate, Evening Primrose oil and Corn oil.
ETHOCYN CREAMS
research reviews & tips
Chantal Ethocyn is a skin care line manufactured by the Chantal Pharmaceutical corporation and is focused on anti-aging treatments. This line is full of products that say they can heal all the aging signs you wish to get rid of, from under eye care to rejuvenation serums. Chantal Ethocyn products say they help firming the skin and give it the youthful healthy appearance women look for. Ethocyn is a new and patented compound synthesized by Dr. Chantal Burnison. Clinical studies at UCLA are showing that Ethocyn works at increasing the production of elastin in the skin tissue.
Because when the skin ages, the enzymes which keep the skin hydrated begin to slow in their production, the Chantal manufacturers spent years of time and millions of dollars to come up with an active ingredient called Ethocyn that can help the skin in producing more elastin fibres, therefore, help it repossess its firmness, only after using the product a few times. Some of the other ingredients found in Chantal Ethocyn skin care line are the following: Cyclomethicone, Squalance, Demithicone, Green Tee Leaf Extract, Tocopheryl Linoleate, Evening Primrose oil and Corn oil.
Clinical studies are available on the company official website and they are full of helpful and detailed information about the products that Chantal Ethocyn offers. And there is as well some information regarding the ingredients and what they are efficient for. You might enjoy reading and acknowledging facts about the ingredients. Also on third party websites there is scientific information to learn more about the effectiveness of the Ethocyn skin care line. The products are available to buy form a number of selected stockists (UK too), or online retailer stores. We did not yet see coupon codes for trial samples or discounts being offered at these shops. Reviews are positive.
Customer's testimonials are not offered in the Chantal website. We always seek to find customer's testimonials in order to gain confidence in the product we intend to purchase, as well as a 100% money back guarantee to take advantage of, if the product did not meet our satisfaction. At the official website such a money back does not seem to be available at the time of this review. However, this Ethocyn skin care line seems to offer a serious alternative you may want to research upon further. Or before deciding, you could be interested in investigating the alternatives
ETHOCYN alternatives are listed in the popular search results. Visit our website AntiAgings.org.uk soon again. From fall on, I am publishing new articles on recent development on anti aging research and skin care products. A new website section dedicated to reviews on ‘Face Care’ will launch in a few weeks.
If you search for the free samples in the search box :
mostly you find the giveaways by searching for the specific Brand Name .
Tip : try to search for giveaways & samples of skin care creams. Many organic make up samples available.
Unfortunately, reliable methods to preserve and/or restore youthful levels of elastin in the skin are scarce at best. That is why the development of Ethocyn in the early 1980s by Dr. Chantal Burnison initially generated so much interest. The problem is that Ethocyn’s effectiveness has not been validated by credible published peer-reviewed studies (at least I haven’t found any) even though the company refers to some proprietary unpublished research. Perhaps the manufacturer (Chantal Pharmaceutical Corporation) didn’t have the budget for the studies comprehensive enough to be published. Or perhaps they were wary of disclosing trade secrets. Or perhaps the supporting data simply wasn’t solid enough. Hopefully, time will tell.
Can Ethocyn restore elasticity to your skin?
Ethocyn (chemical name: ethoxyhexyl-bicyclooctanone) is claimed to stimulate the synthesis of elastin in the skin. If true, such capacity would be highly valuable in skin rejuvenation. Elastin is a protein responsible for the skin’s ability to bounce back after being stretched. The levels of elastin markedly decline with age, which is one of the major factors in the development of the signs of aging. (See our article about elastin.)
Unfortunately, reliable methods to preserve and/or restore youthful levels of elastin in the skin are scarce at best. That is why the development of Ethocyn in the early 1980s by Dr. Chantal Burnison initially generated so much interest. The problem is that Ethocyn’s effectiveness has not been validated by credible published peer-reviewed studies (at least I haven’t found any) even though the company refers to some proprietary unpublished research. Perhaps the manufacturer (Chantal Pharmaceutical Corporation) didn’t have the budget for the studies comprehensive enough to be published. Or perhaps they were wary of disclosing trade secrets. Or perhaps the supporting data simply wasn’t solid enough. Hopefully, time will tell.
Ethocyn molecule is claimed to have a number of physiological effects. Importantly, it blocks the action of the androgenic sex hormone dehydrotestosterone (DHT). It is a well-established fact that DHT levels increase with age. Ethocyn makers claim that age-related decline of elastin synthesis is caused mainly by high level of DHT. Therefore, topical application of Ethocyn presumably blocks DHT in the skin and thereby stimulates elastin synthesis. Such mechanism of action is conceivable but there are serous reservations. In particular, there is little, if any, credible published research proving that high DHT levels suppress the synthesis of elastin. Perhaps the makers of Ethocyn established that fact themselves. Still, an independent peer-reviewed corroboration would help.
Let us assume DHT indeed suppresses elastin synthesis in the skin. Then any agent blocking DHT action or reducing DHT levels would presumably help restore elastin to the skin. Many such agent are known, such as finasteride, dutasteride, spironolactone and so forth. Yet there is no evidence that any anti-DHT agent (except, allegedly, Ethocyn) boosts elsatin synthesis. Perhaps anti-DHT drugs simply have not been studied in that connection. Or perhaps the link between DHT and elastin synthesis, if any, is not causative. Again, more credible research is needed.
Ultimately it is more important to prove that Ethocyn indeed increases elastin synthesis than to establish its exact mechanism of action, whether involving DHT blockade or not. Perhaps the anti-DHT effects of Ethocyn are irrelevant and it boosts elastin via some other pathway. This would still be very good news. However, as long as Ethocyn is backed only by unpublished proprietary research, is it difficult to take its merits at “face value”.
Bottom line
Ethocyn holds a promise of boosting skin elastin and thereby improving signs of aging. An intriguing mechanism of its action (the blockade of dehydrotestosterone in the skin) has been proposed. However, independent published research corroborating these claims is scarce at best.
“There’s a lot of disappointment now,” a weary-sounding Burnison said in a phone interview from New York after several days of damage-control with investors, securities analysts and journalists. In two weeks, the company’s stock has lost nearly 75% of its value, plunging from a high of $28 to close at $7.50, up 87.5 cents, in Nasdaq trading Friday.
Older and Wiser? : Chantal Learns Firsthand That Success Often Brings Scrutiny
Chantal Burnison was flying high, hobnobbing with the likes of Tony Curtis, Barbara Eden and Morgan Fairchild at a celebrity-studded bash to promote her company’s anti-wrinkle cream at an exclusive Beverly Hills hotel in November 1994.
Word of the pricey cosmetic cream, called Ethocyn, touted by the company as a “miraculous molecule,” was spreading rapidly among the affluent and aging. And soon Burnison’s firm, Chantal Pharmaceutical Corp., would be basking in favorable headlines: “Skin Care Breakthrough May Be Fountain of Youth,” trumpeted one drugstore trade publication.
Moreover, Chantal stock was on the verge of an eye-popping roll, propelled by breathless forecasts by an obscure investment firm that Ethocyn sales would hit $200 million a year in three years.
But Chantal’s reputation developed a nasty blemish last week when news reports questioned the effectiveness of the company’s product and its ability to compete with a new wrinkle cream from Johnson & Johnson. Burnison, a chemist who feels more comfortable in the research laboratory than at investors’ confabs, was ill-prepared for what followed: a punishing lesson in the ways of Wall Street.
“There’s a lot of disappointment now,” a weary-sounding Burnison said in a phone interview from New York after several days of damage-control with investors, securities analysts and journalists. In two weeks, the company’s stock has lost nearly 75% of its value, plunging from a high of $28 to close at $7.50, up 87.5 cents, in Nasdaq trading Friday.
“We have a company with a product on which we’ve done $17 million in research. . . . I’m convinced the product works,” says Burnison, 45, who uses Ethocyn herself.
If these events weren’t bad enough, Burnison canceled an investors’ meeting in New York on Thursday to return to Los Angeles after her mother became seriously ill. That sparked Wall Street rumors that Burnison had fled the country, a company spokesman said.
On Friday, Burnison denounced what she called “vicious rumors and outright lies” about her and the company. Chantal said it would ask the Securities and Exchange Commission and National Assn. of Securities Dealers to investigate unusually high trading volume in the stock. Company and investment sources blame the rumors on short-sellers, who make money by speculating on stocks whose prices they expect to fall.
With such troubles, it may take more than the New York “crisis management” consultant Chantal hired to shore up the Los Angeles-based company’s reputation.
Chantal’s woes show what can happen when a company is ill-prepared to handle the closer scrutiny that often comes with sudden success. And it demonstrates how marketing hype–especially when it flirts with claims of medical breakthroughs–can backfire when subjected to more scrutiny.
The trouble came in news reports–including a highly critical article in Barron’s magazine–that questioned the effectiveness of her company’s product and the validity of Ethocyn sales figures. The business weekly also questioned the reputation of Chantal’s chief marketer and distributor, a smooth-talking sales executive who has hawked car-cleaning wands and Wacky WallWalkers, fad toy octopuses that wiggled down walls. Along with that came rumors that federal regulators were investigating Chantal’s marketing claims.
The company said it will hire the accounting firm Coopers & Lybrand to conduct an independent audit of its distributor, Los Angeles-based Stanson Marketing, focusing on sales figures. The company also promised to convene a telephone conference call for investors with “nationally recognized dermatologists and skin care experts” to vouch for Ethocyn.
Burnison, a chemist and lawyer, founded the company 13 years ago in a small laboratory in a factory owned by her father, Eugene Burnison, inventor of the pneumatic nail gun used by carpenters. Financing for the company’s early research came through a deal Burnison struck with her father: He promised to fund her research if she agreed to go to law school instead of medical school, as she had planned. He hoped that a law degree would help her take over his company when he retired, Chantal Burnison says.
(Last week, Chantal said that a company owned by Burnison’s father and other family members, CBD Pharmaceutical Corp., sold 300,000 of its 1.4 million shares of Chantal stock in December for more than $20 a share. Burnison says the decision was made by her father to raise capital for a new business venture and that she has sold none of the 1.5 million shares she personally owns.)
The company has patented three chemical compounds known as anti-androgens that it has targeted for use on male-pattern baldness, certain cancers and acne and other skin conditions.
Only one of those compounds, Ethocyn, has developed into a product. Ethocyn is sold as a nonprescription cosmetic at 14,000 drugstores nationwide, and the firm will soon announce deals with two major drugstore chains to carry the product, company officials said.
Chantal’s sales reached $7.2 million for the year ended June 30. For the three months ended Sept. 30, sales rose sharply, to $10.9 million.
William Gibson, an analyst at Cruttenden Roth in Santa Barbara, whose forecasts of $200 million in annual revenue by 1997 have helped propel Chantal stock, says he has checked with retailers around the country and been told that Ethocyn is selling well. At the 328-store Longs Drugs chain, Ethocyn sales are “exceeding our original projections,” spokesman Clay Selland says. “It’s something our customers are asking for.”
A two-month supply of Ethocyn costs $75. But the product faces competition from Johnson & Johnson’s Renova, which last month received FDA approval for sale as the first prescription medication to help reduce wrinkles. Renova, which will cost only $25 to $30 for a two-month supply, is a version of Retin-A, the prescription acne medication.
Chantal has promoted Ethocyn through a costly marketing campaign that includes television spots and magazine advertisements in Vogue, Ladies Home Journal and Town & Country. The ad campaign is highlighted by a testimonial from Karen Phillips, a 57-year-old accountant at Chantal who says she personally tested Ethocyn by applying it to only half her face and neck for nearly one year. The magazine ads show an unretouched photograph of Phillips in which significantly fewer wrinkles are visible on the side of her face and neck that she says was treated with Ethocyn.
The ad touts the product as “a molecule so miraculous we patented it.”
Chantal’s claims for Ethocyn’s anti-aging effects rely primarily on clinical trials conducted by Richard Strick, a clinical professor of dermatology at UCLA. After four years of research, funded by Chantal, Strick presented his findings at the American Academy of Dermatology in 1994.
In a study of 29 patients age 40 or older, Strick reported that Ethocyn increased elastin content in the skin an average of 100%, and sometimes as much as 500% in patients with an already low elastin content. As people age, the skin loses its elastin, which frequently causes wrinkles or sagging skin, Strick explains.
“There is no doubt whatsoever in my mind that this works,” said Strick, who has made public appearances on behalf of Chantal but says he has no financial interest in the firm.
Other dermatologists report seeing positive effects on patients who have been using Ethocyn.
Ronald Bronow, a West Los Angeles dermatologist who has about 50 patients using Ethocyn, says roughly 60% are pleased with the results.
Bronow says he has “never seen these kind of changes with moisturizers” or other skin-care products. “I think this product is probably for real.”
Some doctors, however, are skeptical.
Peter Goldman, a Los Angeles dermatologist and associate clinical professor at UCLA Medical School, says 10 to 20 of his patients have used Ethocyn and most “have not been particularly thrilled that it’s done as much as promised.”
Goldman says Strick’s findings should be considered “very preliminary” because his research did not use a control group. “It was surprising to many of us how, based on such limited data, there was so much hoopla created by Chantal,” he says.
Stephen Tucker, a dermatology professor at the University of Texas Medical Center in Houston, has completed a three-month placebo-controlled study of 20 patients using Ethocyn. The data will be analyzed by Strick, he says. Noting that Strick also conducted the first study, Tucker said the purpose of the “blinded” study is to eliminate any possibility of researcher bias.
But if the new study shows Ethocyn is effective, it could create more problems for Chantal. If Ethocyn really has an effect on the structure or function of the skin, FDA officials might require that it be approved as a drug–a lengthy and costly process.
In fact, Chantal sought FDA approval to begin clinical trials for Ethocyn in 1988 but put the application on hold because it did not want to spend the money, says Robert Pinco, a Washington attorney who represents Chantal in FDA matters and is a Chantal director. Chantal makes no medical claims about Ethocyn, Pinco says, adding: “We don’t say how it works or what happens.”
The company wasn’t always so cautious. In an October 1994 press release, Chantal claimed that Ethocyn “dramatically affects the elasticity and resiliency of the skin.”
The FDA, meanwhile, is aware of the controversy involving Ethocyn and has begun a “fact-finding” review of Chantal’s marketing claims, not a formal investigation, said John Bailey, director of the FDA’s Office of Cosmetic and Colors.
Bailey says companies are not permitted to sell products as cosmetics while promoting their drug-like effects. “You can’t have it both ways,” he says.